Pfizer Inc
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Elrexfio (elranatamab by Year
Elrexfio (elranatamab — BCMA bispecific for multiple myeloma) — Worldwide revenues ($M) ($M)
Pfizer Elrexfio (elranatamab: $304M in FY2025, up 128.6% from a year earlier.
Where the FY2025 figure comes from
“|| Elrexfio | 304 | 133 | * | * | 143 | 88 | 63% | 161 | 45 | * | *”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Elrexfio (elranatamab — BCMA bispecific for multiple myeloma) — Worldwide revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 304 | +128.6% | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 133 | +1,230.0% | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
| FY2023 | Dec 31, 2023 | 10 | – | Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗ |
| FY2022 | Dec 31, 2022 | 0 | – | Form 10-K (filed 2025-02-27) ↗ |
Breakdown
What makes up elrexfio (elranatamab
- Elrexfio (elranatamab — BCMA bispecific for multiple myeloma) — U.S. revenues ($M)143 · FY2025
- Elrexfio (elranatamab — BCMA bispecific for multiple myeloma) — International revenues ($M)161 · FY2025
- Elrexfio (elranatamab — BCMA bispecific for multiple myeloma) — Worldwide reported YoY (%)–
- Elrexfio (elranatamab — BCMA bispecific for multiple myeloma) — Worldwide operational (constant-currency) YoY (%)–
Cite this data
StockData. (2026). Pfizer Elrexfio (elranatamab ($M), annual FY2022–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/elrexfio-ww
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.